The likely mechanisms of Ad-36 involved in NAFLD consist in reducing leptin gene expression and insulin sensitivity, increasing glucose uptake, activating the lipogenic and pro-inflammatory pathways in adipose tissue, leading to chronic inflammation and affecting lipid metabolism. Here, LEP is linked to metabolic dysfunction-associated steatotic liver disease.